canimmunize

Wellteq to Integrate Digital Vaccination Records Through Strategic Partnership With CANImmunize

  • Wellteq (CSE.WTEQ) (OTC.WTEQF) has signed a letter of intent for a strategic partnership agreement with CANImmunize Inc. to incorporate digital vaccination records with enterprise wellness into integrated solutions. Since 2011, CANImmunize has been a pioneer of digital immunization policy and solutions on a Canadian and international level.

  • CANImmunize is recognized by the European Center for Disease Prevention and Control as a model for consumer facing immunization solutions and canimmunize.ca is certified by the WHO VaccineSafetyNet.

  • The Partnership with CANImmunize will integrate developed and tested immunization information systems with Wellteq's digital health and wellness platform capabilities for enterprises and their employees.

  • Integration projected to be completed during 2021.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

WellteQ Digital Health Inc. (CSE:WTEQ) (OTC:WTEQF) (the "Company" or "Wellteq") is pleased to announce the Company has signed a letter of intent (the "LOI") detailing the general terms of a strategic partnership with CANImmunize Inc., an Ottawa-based technology company specializing in immunization software solutions. The strategic partnership will create varied offerings incorporating digital vaccination records and enterprise wellness for a variety of corporate customers initially across Canada and Asia Pacific, then more broadly.

Due to COVID-19, countries and organizations are facing immediate challenges in creating immunization information systems that can effectively and accurately track vaccinations. The return to normal activities and the migration of people across regional and national borders and the increasingly fragmented nature of immunization practice with individuals receiving information from multiple different providers are major obstacles to having comprehensive immunization status.

The CANImmunize team has over a decade of experience developing digital immunization solutions for businesses, health care organizations and governments, including COVID-19 vaccination software. CANImmunize has developed the internationally recognized CANImmunize app, a pan-Canadian digital immunization tracking system that helps Canadians keep track of their vaccinations with a mobile app and web portal. Users of the CANImmunize app can see their immunization records, get accurate information on vaccinations, receive reminders about immunizations and alerts about vaccine-preventable diseases. The app is recognized by the European Centre for Disease Prevention and Control as a model for consumer facing immunization solutions and canimmunize.ca is certified by the WHO VaccineSafetyNet.

"CANImmunize is excited to collaborate with Wellteq on this strategic partnership," stated Dr. Kumanan Wilson, CEO of CANImmunize and a physician-researcher at The Ottawa Hospital. "The COVID-19 pandemic has underscored the importance of keeping employees safe and healthy. We look forward to combining our 10 years' experience in developing immunization solutions with Wellteq's expertise to ensure the well-being of employees."

Scott Montgomery, CEO of Wellteq, stated, "The days of prescribing pills as the default form of healthcare are coming to an end. The transformation of healthcare to being more proactive and preventive is here, it's happening now. By offering vaccination records seamlessly alongside wellness coaching, we offer employers and insurers the best proactive and preventive healthcare available. Wellteq is incredibly excited to offer this integrated healthcare solution across APAC, Canada and soon globally."

About CANImmunize Inc.

CANImmunize is a science-based technology company specializing in immunization software. The team has over 10 years' experience developing digital immunization solutions for businesses, health care organizations and governments, including COVID-19 vaccination software, tracking and other immunization needs. It developed the internationally-recognized CANImmunize app, a pan-Canadian digital immunization tracking system that helps Canadians keep track of their vaccinations with a mobile app and web portal.

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model, Wellteq currently has two main sectors of customers: employers and insurance companies. Wellteq has secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners, like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare.

Investor Contact:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888
Sales & Partnership Contact:

stacey@wellteq.co

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

Latest Press Releases

Related News

×